Hyperglycemia in a Coronary Intensive Care Unit
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00984737|
Recruitment Status : Completed
First Posted : September 25, 2009
Last Update Posted : September 25, 2009
|Condition or disease||Intervention/treatment|
|Diabetes Mellitus Hyperglycemia Blood Glucose Myocardial Ischemia||Drug: Insulin|
Patients with acute coronary heart disease admitted to the emergency room will be recruited consecutively. Admission plasma glucose (APG) and fasting plasma glucose (FPG); the first morning after admission, measurements will be obtained and each participant will be subjected to capillary glucose measurement (CGM) every six hours within the first day.
Patients will be separated into 4 groups:
GROUP 1: Normoglycemic cases GROUP 2: Newly diagnosed hyperglycemic cases Group 2a: Unrecognized diabetes, hbA1c: >6.0% Group 2b: Stress hyperglycemia <6.0%. GROUP 3: Known diabetes Age, gender, co-morbidities on admission, adverse outcomes in hospital, duration of stay in coronary ICU, deaths, drugs, and glucose levels will be all recorded.
Throughout the hospital stay of Group 2 and Group 3, CGMs were performed and treated when necessary (target glucose<180mg/dl).
Acute Physiology and Chronic Health Evaluation II (APACHE-II); a severity of disease classification system was used for each case.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Newly Diagnosed Hyperglycemia and Stress Hyperglycemia in a Coronary Intensive Care Unit|
|Study Start Date :||May 2007|
|Primary Completion Date :||November 2008|
|Study Completion Date :||November 2008|
Capillary glucose measurements of Group 2 and Group 3 will be performed during hospitalization and will be treated when they are over 180mg/dl.
Short acting oral anti-diabetic drugs will be given to patients who refuse insulin injection.
- To determine the prevalence of newly diagnosed hyperglycemia in coronary ICU.
- To search for the cases with stress hyperglycemia and inquire its relationship with disease severity and functional outcomes, such as longevity of ICU stay.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00984737
|Baskent University Faculty of Medicine, Adana Medical Center|
|Adana, Turkey, 01250|